PMC:7047369 / 2211-3766 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"74","span":{"begin":17,"end":23},"obj":"Species"},{"id":"75","span":{"begin":8,"end":16},"obj":"Disease"},{"id":"78","span":{"begin":238,"end":244},"obj":"Chemical"},{"id":"79","span":{"begin":531,"end":537},"obj":"Chemical"},{"id":"81","span":{"begin":1076,"end":1084},"obj":"Species"}],"attributes":[{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"Tax:9606"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:D007239"},{"id":"A78","pred":"tao:has_database_id","subj":"78","obj":"MESH:D010100"},{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"MESH:D010100"},{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"How are infected people being treated?\nThere is no proven treatment at this early stage but we will doubtless have more information about this soon. It can be assumed that non-pharmacologic approaches are effective such as fluid support, oxygen and ventilatory support. Most recently the national data suggests that 17.7%, 10.4% and 7.0% of all cases have disease requiring respiratory support in Wuhan, Hubei (not including Wuhan) and the rest of China (respectively). About a quarter of all require ventilation while 75% require oxygen support only. The variation in severity rates probably reflects the outcomes in an overwhelmed health system. Extra Corporeal Membrane Oxygenation (ECMO) is potentially of benefit and we will know more particularly when cities with higher technology health systems become affected and ECMO is truly tested in the most severely ill. ECMO is currently being used in China, however, its effectiveness is yet to be determined.\nAntiviral drugs as well as a variety of other putative treatments are typically being prescribed for deteriorating patients on a compassionate basis. Clinicians would be well aware of such situations but assurance is required that their safety and efficacy are being scientifically assessed so that meaning is brought to bear quickly. Coordination of clinical trials to avoid duplication and ensure that results are rapidly available will be a challenge but the case numbers should facilitate rapid definitive results. (see What is in the pipeline for vaccine development and/or therapeutics?)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T90","span":{"begin":176,"end":189},"obj":"CHEBI:52217;CHEBI:52217"},{"id":"T89","span":{"begin":374,"end":385},"obj":"UBERON:0001004"},{"id":"T88","span":{"begin":961,"end":970},"obj":"CHEBI:35718;CHEBI:35718"},{"id":"T87","span":{"begin":971,"end":976},"obj":"CHEBI:36044;CHEBI:36044"}],"text":"How are infected people being treated?\nThere is no proven treatment at this early stage but we will doubtless have more information about this soon. It can be assumed that non-pharmacologic approaches are effective such as fluid support, oxygen and ventilatory support. Most recently the national data suggests that 17.7%, 10.4% and 7.0% of all cases have disease requiring respiratory support in Wuhan, Hubei (not including Wuhan) and the rest of China (respectively). About a quarter of all require ventilation while 75% require oxygen support only. The variation in severity rates probably reflects the outcomes in an overwhelmed health system. Extra Corporeal Membrane Oxygenation (ECMO) is potentially of benefit and we will know more particularly when cities with higher technology health systems become affected and ECMO is truly tested in the most severely ill. ECMO is currently being used in China, however, its effectiveness is yet to be determined.\nAntiviral drugs as well as a variety of other putative treatments are typically being prescribed for deteriorating patients on a compassionate basis. Clinicians would be well aware of such situations but assurance is required that their safety and efficacy are being scientifically assessed so that meaning is brought to bear quickly. Coordination of clinical trials to avoid duplication and ensure that results are rapidly available will be a challenge but the case numbers should facilitate rapid definitive results. (see What is in the pipeline for vaccine development and/or therapeutics?)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T23","span":{"begin":476,"end":477},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T24","span":{"begin":664,"end":672},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"},{"id":"T25","span":{"begin":837,"end":843},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T26","span":{"begin":988,"end":989},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T27","span":{"begin":1088,"end":1089},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T28","span":{"begin":1403,"end":1404},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"How are infected people being treated?\nThere is no proven treatment at this early stage but we will doubtless have more information about this soon. It can be assumed that non-pharmacologic approaches are effective such as fluid support, oxygen and ventilatory support. Most recently the national data suggests that 17.7%, 10.4% and 7.0% of all cases have disease requiring respiratory support in Wuhan, Hubei (not including Wuhan) and the rest of China (respectively). About a quarter of all require ventilation while 75% require oxygen support only. The variation in severity rates probably reflects the outcomes in an overwhelmed health system. Extra Corporeal Membrane Oxygenation (ECMO) is potentially of benefit and we will know more particularly when cities with higher technology health systems become affected and ECMO is truly tested in the most severely ill. ECMO is currently being used in China, however, its effectiveness is yet to be determined.\nAntiviral drugs as well as a variety of other putative treatments are typically being prescribed for deteriorating patients on a compassionate basis. Clinicians would be well aware of such situations but assurance is required that their safety and efficacy are being scientifically assessed so that meaning is brought to bear quickly. Coordination of clinical trials to avoid duplication and ensure that results are rapidly available will be a challenge but the case numbers should facilitate rapid definitive results. (see What is in the pipeline for vaccine development and/or therapeutics?)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3","span":{"begin":238,"end":244},"obj":"Chemical"},{"id":"T4","span":{"begin":531,"end":537},"obj":"Chemical"},{"id":"T5","span":{"begin":971,"end":976},"obj":"Chemical"}],"attributes":[{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"How are infected people being treated?\nThere is no proven treatment at this early stage but we will doubtless have more information about this soon. It can be assumed that non-pharmacologic approaches are effective such as fluid support, oxygen and ventilatory support. Most recently the national data suggests that 17.7%, 10.4% and 7.0% of all cases have disease requiring respiratory support in Wuhan, Hubei (not including Wuhan) and the rest of China (respectively). About a quarter of all require ventilation while 75% require oxygen support only. The variation in severity rates probably reflects the outcomes in an overwhelmed health system. Extra Corporeal Membrane Oxygenation (ECMO) is potentially of benefit and we will know more particularly when cities with higher technology health systems become affected and ECMO is truly tested in the most severely ill. ECMO is currently being used in China, however, its effectiveness is yet to be determined.\nAntiviral drugs as well as a variety of other putative treatments are typically being prescribed for deteriorating patients on a compassionate basis. Clinicians would be well aware of such situations but assurance is required that their safety and efficacy are being scientifically assessed so that meaning is brought to bear quickly. Coordination of clinical trials to avoid duplication and ensure that results are rapidly available will be a challenge but the case numbers should facilitate rapid definitive results. (see What is in the pipeline for vaccine development and/or therapeutics?)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T21","span":{"begin":0,"end":38},"obj":"Sentence"},{"id":"T22","span":{"begin":39,"end":148},"obj":"Sentence"},{"id":"T23","span":{"begin":149,"end":269},"obj":"Sentence"},{"id":"T24","span":{"begin":270,"end":469},"obj":"Sentence"},{"id":"T25","span":{"begin":470,"end":551},"obj":"Sentence"},{"id":"T26","span":{"begin":552,"end":647},"obj":"Sentence"},{"id":"T27","span":{"begin":648,"end":960},"obj":"Sentence"},{"id":"T28","span":{"begin":961,"end":1110},"obj":"Sentence"},{"id":"T29","span":{"begin":1111,"end":1295},"obj":"Sentence"},{"id":"T30","span":{"begin":1296,"end":1555},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"How are infected people being treated?\nThere is no proven treatment at this early stage but we will doubtless have more information about this soon. It can be assumed that non-pharmacologic approaches are effective such as fluid support, oxygen and ventilatory support. Most recently the national data suggests that 17.7%, 10.4% and 7.0% of all cases have disease requiring respiratory support in Wuhan, Hubei (not including Wuhan) and the rest of China (respectively). About a quarter of all require ventilation while 75% require oxygen support only. The variation in severity rates probably reflects the outcomes in an overwhelmed health system. Extra Corporeal Membrane Oxygenation (ECMO) is potentially of benefit and we will know more particularly when cities with higher technology health systems become affected and ECMO is truly tested in the most severely ill. ECMO is currently being used in China, however, its effectiveness is yet to be determined.\nAntiviral drugs as well as a variety of other putative treatments are typically being prescribed for deteriorating patients on a compassionate basis. Clinicians would be well aware of such situations but assurance is required that their safety and efficacy are being scientifically assessed so that meaning is brought to bear quickly. Coordination of clinical trials to avoid duplication and ensure that results are rapidly available will be a challenge but the case numbers should facilitate rapid definitive results. (see What is in the pipeline for vaccine development and/or therapeutics?)."}